everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...89101112131415161718...132133»
  • ||||||||||  bortezomib / Generic mfg., sirolimus / Generic mfg.
    Journal:  Inhibitors of the Mechanistic Target of Rapamycin Can Ameliorate Bortezomib-Induced Peripheral Neuropathy. (Pubmed Central) -  Aug 2, 2023   
    Bortezomib-induced allodynia was accompanied by the activation of spinal astrocytes, and intrathecal injection of mTOR inhibitors or an inhibitor of ribosomal protein S6 kinase 1, a downstream target of mTOR, exhibited considerable analgesic effects in a dose-dependent manner. These results suggest that mTOR inhibitors, which are readily available to patients prescribed bortezomib, are one of the most effective therapeutics for bortezomib-induced peripheral neuropathy.
  • ||||||||||  lamivudine HBV / Generic mfg.
    Acute Liver Failure Due to Discontinuation of Hepatitis B Virus (HBV) Therapy (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_2976;    
    The patient was virally suppressed for several years on lamivudine but switched to tenofovir due to viral breakthrough...The patient is discharged one week after surgery on entecavir, along with immunosuppression regimen of tacrolimus, prednisone and mycophenolate...After these episodes, mycophenolate dosage is decreased and everolimus is initiated for renal sparing immunosuppressive therapy...Providers should educate patients on the risks of stopping medication and the devastating consequences of viral breakthrough. Additional patient education on how to approach lapses in health insurance may also be helpful in these cases.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Journal, Gene therapy:  Liver Injury in Cynomolgus Monkeys Following Intravenous and Intrathecal scAAV9 Gene Therapy Delivery. (Pubmed Central) -  Jul 29, 2023   
    Self-complementary AAV-induced acute liver injury appears to correlate with high hepatocellular vector load, macrophage activation and type-1 interferon innate virus-sensing pathway responses. The current work further characterizes key aspects pertaining to early AAV-driven hepatotoxicity in cynomolgus macaques, highlighting the usefulness of this nonclinical species in that context.
  • ||||||||||  Inlyta (axitinib) / Pfizer, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases:  Cost-effectiveness analysis of cabozantinib compared with everolimus, axitinib, and nivolumab in subsequent line advanced renal cell carcinoma in Japan. (Pubmed Central) -  Jul 28, 2023   
    Efficacy and safety data from METEOR were used as a proxy for the Japanese population following validation by clinical experts, and alternative assumptions specific to clinical practice in Japan were evaluated in scenario analyses. In Japan, cabozantinib is a cost-effective alternative to everolimus, axitinib, and nivolumab for the treatment of patients with advanced renal cell carcinoma who have received at least one prior line of therapy.
  • ||||||||||  everolimus / Generic mfg.
    Journal, Tumor mutational burden, IO biomarker:  Integrated analysis of FKBP1A/SLC3A2 axis in everolimus inducing ferroptosis of breast cancer and anti-proliferation of T lymphocyte. (Pubmed Central) -  Jul 28, 2023   
    Noteworthily, everolimus (a targeted therapy drug for BC) related protein, FK506-binding protein 1A (FKBP1A) was found to bind with SLC3A2, and negatively regulated SLC3A2 expression during the processes of everolimus inducing ferroptosis of BC cells and promoting anti-proliferation of Th9 lymphocytes. Altogether, our study strongly implies that SLC3A2 is an immuno-oncogenic factor and FKBP1A/SLC3A2 axis would provide insights for a novel immunotherapy approach for the treatment of BC in the context of TME.
  • ||||||||||  Piqray (alpelisib) / Novartis, imlunestrant (LY3484356) / Eli Lilly
    Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study (Bilbao Auditorium - NCC) -  Jul 27, 2023 - Abstract #ESMO2023ESMO_795;    
    P1a/1b
    In the first-in-human phase 1a/b EMBER study, imlunestrant demonstrated favorable safety, pharmacokinetics (PK), and clinical benefit rate when administered as monotherapy (Jhaveri ASCO 2022) or with abemaciclib (Jhaveri SABCS 2022)...Median number of prior aBC therapies in combination cohorts was: 1 (range 1-2); including prior ET (100%), CDK4/6i (100%), fulvestrant (35%) and chemo (17%)...Conclusions Imlunestrant alone or in combination with everolimus or alpelisib demonstrated robust efficacy in pts with pre-treated ER+, HER-2 aBC. Toxicities were consistent with the known safety profile of both alpelisib and everolimus.
  • ||||||||||  Rozlytrek (entrectinib) / Roche
    Entrectinib Amazing Efficacy in a Case of Lung Atypical Carcinoid with NTRK Gene Fusion (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1798;    
    We present the case of a patient with lung atypical carcinoid with NTRK gene fusion on re-biopsy after multiple line therapy failure of platinum-based chemotherapy , targeted therapy, even immunotherapy . Entrectinib seventh line of therapy, achieved complete response, which emphasizing the efficacy of this selective NTRK kinase inhibitor on this rare neuroendocrine tumor with NTRK fusion.
  • ||||||||||  Krazati (adagrasib) / Mirati, ARS-1620 / Kura Oncology, J&J, Araxes Pharma, Lumakras (sotorasib) / Amgen
    Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_1213;    
    Combination of KRAS G12C inhibitor (AMG-510, MRTX849, and ARS-1620) and mTOR inhibitor (Everolimus) showed synergism in both adenocarcinoma and squamous cell carcinoma cell lines. The targetable somatic variant G12C in KARS should be explored in squamous cell carcinoma as well as in adenocarcinoma.
  • ||||||||||  sirolimus / Generic mfg.
    Journal:  Clinical and radiological improvement in Gorham-Stout disease after sirolimus treatment. (Pubmed Central) -  Jul 23, 2023   
    Oral sirolimus treatment for GSD inhibits angiogenesis and osteoclastic activity, stimulating bone anabolism and leading to arrested osteolysis progression and improved ossification, quality of life, and patient prognosis. Therefore, sirolimus should be considered a therapeutic option for this rare disease.
  • ||||||||||  everolimus / Generic mfg., erlotinib / Generic mfg.
    Journal:  mTORC1 Signaling and Negative Lens-Induced Axial Elongation. (Pubmed Central) -  Jul 23, 2023   
    Therefore, sirolimus should be considered a therapeutic option for this rare disease. (1) To investigate whether EGFR is the upstream regulator of mTORC1, an EGFR inhibitor (20
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg.
    Journal:  Risk factors for fractures following liver transplantation: a population-based cohort study. (Pubmed Central) -  Jul 21, 2023   
    The liver transplant recipients, and especially those who were aged ?65?years, female, hepatitis C carriers, had a history of fractures within 1?year prior to transplant, alcoholism, and higher daily prednisolone dose were associated with an increased risk of post-transplant fractures. Conversely, the use of tacrolimus and sirolimus/everolimus was associated with a decreased risk of fractures.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Gilotrif (afatinib) / Boehringer Ingelheim, Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Enrollment open, Trial primary completion date, Tumor cell:  Pilot Trial for Treatment of Recurrent Glioblastoma (clinicaltrials.gov) -  Jul 21, 2023   
    P1,  N=10, Recruiting, 
    Efficacy and safety for patients in the East Asian subset were generally similar to those of the global population, except as noted. Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2027 --> Jul 2027
  • ||||||||||  everolimus / Generic mfg., sorafenib / Generic mfg.
    Trial completion date, Trial primary completion date:  Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer (clinicaltrials.gov) -  Jul 20, 2023   
    P2,  N=41, Active, not recruiting, 
    Recruiting --> Completed | N=15 --> 8 Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2023 --> Jun 2025
  • ||||||||||  New P1 trial:  Rapalog Pharmacology (RAP PAC) Study (clinicaltrials.gov) -  Jul 20, 2023   
    P1,  N=72, Not yet recruiting, 
  • ||||||||||  everolimus / Generic mfg.
    Review, Journal:  Rapamycin and rapalogs for tuberous sclerosis complex. (Pubmed Central) -  Jul 15, 2023   
    Topical rapamycin increases the response to skin lesions and facial angiofibroma, an improvement score, satisfaction and the risk of any AE, but not severe adverse events. With caution regarding the risk of severe AEs, this review supports oral everolimus for renal angiomyolipoma, SEGA, seizure, and skin lesions, and topical rapamycin for facial angiofibroma.
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg.
    Journal:  Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes. (Pubmed Central) -  Jul 14, 2023   
    Unfortunately, 9 and 11 showed limited oral exposures in higher species and dose-limiting toxicities in cynomolgus macaque, respectively. However, they remain optimal tools to explore mTOR hyperactivity in CNS disease models.
  • ||||||||||  avutometinib (VS-6766) / Verastem
    Trial completion date, Trial primary completion date, Combination therapy:  DDU RAF/MEK: Phase I Trial of VS-6766 Alone and in Combination With Everolimus (clinicaltrials.gov) -  Jul 14, 2023   
    P1,  N=104, Recruiting, 
    However, they remain optimal tools to explore mTOR hyperactivity in CNS disease models. Trial completion date: Feb 2023 --> May 2024 | Trial primary completion date: Feb 2023 --> May 2024